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INTRODUCTION 
Acetaminophen is a commonly used analgesic and antipyretic which when taken in 
recommended doses is both safe and effective. However, acetaminophen ingested in large doses, 
such as encountered in suicide attempts, ma/ result in massive, sometimes fatal, hepatic and 
renal n e c r o s i s , ' " 4 
Acetaminophen-induced hepatotoxicity results from the metabolic conversion of 
acetaminophen to a quantitatively minor reactive metabolite by cytochrome P-450-mediated 
oxidation 5 ' 6 Direct inhibition of this route of metabolism may be useful in the treatment of 
acetaminophen overdose, possibly as an adjunct to N - a c e t y l c y s t e i n e 7 ~ 1 3 To date, few 
clinical trials have been conducted to support the use of of cytochrome P - 4 5 0 Inhibitors in 
this setting. Moreover, studies with cimetidine have reported conflicting results concerning 
potential efficacy.®"1 1 Another drug, metyrapone, also an inhibitor of cytochrome 
P-450-mediated oxidation, has been shown to protect mice from the lethal effects of 
acetaminophen under simulated overdose conditions. ' 2 , 1 3 
The purpose of this study was to assess the effect of metyrapone administration on the 
elimination kinetics and metabolic fate of acetaminophen in man, employing normal 
therapeutic doses of acetaminophen in order to ascertain the potential clinical utility of 
metyrapone administration as an antidote for acetaminophen poisoning. 
Background 
Acetaminophen first became available in the United States in 1955 as a prescription 
analgesic and antipyretic. In 1 9 6 0 , the drug was approved by the Food and Drug 
2 
Administration for non-prescription use. The association of acetaminophen with severs liver 
injury was not recognized until 1 9 6 6 when two Scottish physicians reported the cases of two 
patients who had ingested l a r p m o u n t s of the drug arrt subsequently developed evidence of 
severe, acute liver injury, and d i a l 1 4 Today, it is widely appreciated that acetaminophen in 
large doses can produce fatal hepatic and renal necrosis in both man and experimental animals. 
Following therapeutic doses, acetaminophen is metabolized primarily by conjugation to 
two non-toxic metabolites, acetaminophen glucuronide and acetaminophen sulfate (Figure 1) . 
These account for 80-90%  of acetamlnophen's metabolites and are excreted primarily in the 
u r i n e , 1 5 » A small percentage of an administered dose is converted to a reactive 
intermediate (probably N-acetyl-imidoquinone) by the cytochrome P - 4 5 0 mixed-function 
oxidase s y s t e m . 6 - ' 7 » ' ® This reactive intermediate is detoxified by conjugation with reduced 
hepatic glutathione. The glutathione metabolite is further metabolized to cysteine aid 
mercapturic acid derivatives before final urinary elimination (Figure 1). 1 5 > 1 6 > 1 9 
Approximately 2 to 5% of a 1 g dose w i l l also appear in the urine as unchanged acetaminophen 
(Figure 1 ) . 1 1 9 A small fraction of unchanged acetaminophen and each metabolite can also 
be recovered in bile, but this route of elimination is quantitatively minor and of little 
importance in humans. 2 0 
Following an acetaminophen overdose, the glucuronide and sulfate metabolic pathways 
become saturated and a larger fraction of the drug is then available to undergo oxidation to the 
reactive Intermediate.21» 2 2 Increased production of this toxic Intermediate leads to the 
depletion of hepatic stores of glutathione. When hepatic glutathione is reduced by 
approximately 7058 or more, the reactive metabolite then covalently binds to hepatic and 
renal macromolecules resulting in tissue necrosis and rail d e a t h . - 2 1 • Individual 
susceptibility to acetaminophen hepatotoxlclty depends on the state of enzyme Induction in the 
3 
individual owl the anoint of protein in the diet. Both factors influence the extent of 
hepatocellular necrosis following acetaminophen p o i s o n i n g , 2 6 " 2 8 
Currently, administration of N-acetylcysteine, a sulfhydryl containing compound, is 
recommended for the treatment of acetaminophen poisoning.1 9 - 2 1 > 2 9 The literature 
suggests that the antidotal effects of N-acetylcysteine are derived from its conversion to 
cysteine and incorporation into glutathione.3 0 A s a result, additional glutathione is available 
fa* conjugation with the reactive intermediate which would result in its inactivation and the 
sparing of renal and hepatic t i m e . 3 1 Additional work by Corcoran et a l 3 2 suggests that 
N-acetylcysteine may prevent acetaminophen-induced hepatocellular necrosis by directly 
decreasing the formation of the reactive intermediate thereby reducing the quantity of reactive 
intermediate available to compete for available stores of hepatic glutathione. 
Recently, a number of reports have appeared in the literature which suggest that the 
inhibition of cytochrome P-450-mediated oxidation of acetaminophen metabolism may be of 
benefit in preventing the hepatic and renal damage frequently encountered in acetaminophen 
o v e r d o s e 1 1 These reports have demonstrated that cimetidine administered to mice aid rats 
after acetaminophen poisoning will prevent the development of hepatic n e c r o s i s . 1 1 » 3 3 
Similar studies carried out in humans with normal therapeutic doses of acetaminophen have 
produced conflicting results. 
In a study by Miners et al^ acetaminophen was administered orally to 12 healthy, male 
subjects on two separate occasions. On the first occasion, or Airing the control phase, the 
subjects received acetaminophen alone. On the second occasion, acetaminophen administration 
was preceded by cimetidine 2 0 0 mg orally every six hours aid 4 0 0 mg at bedtime for seven 
days. On both occasions, acetaminophen elimination kinetics aid metabolic fate were 
determined by collection of saliva aid urine specimens. There was no difference in the 
4 
urinary excretion profile and metabolic clearance of acetaminophen and its metabolites after 
cimetidine treatment. This suggests that cimetidine pretreatment had no effect on oxidative 
metabolism ami therefore did not inhibit the formation of the reactive intermediate and would 
be of no value in the treatment of acetaminophen poisoning. 
A study was conducted by Critchley et a l 8 in which acetaminophen was administered orally 
to ten healthy, male subjects on two separata occasions separated by at least seven days. On 
the first occasion, acetaminophen was administered alone and urine was collected from the 
subjects for 2 4 hours. The urinary composition of metabolites was then determined by high 
pressure liquid chromatography. On the second occasion, cimetidine 800 mg was administered 
orally one hour prior to acetaminophen and additional doses were given 4 , 8 and 1 2 hours 
after the dose of acetaminophen. A comparison of the urinary recovery of acetaminophen and 
metabolites between the control aid cimetidirw treatment periods revealed no difference In the 
quantity of the oxidative metabolites recovered. Like Miners et al J Critchley and associates8 
failed to confirm the potential usefulness of cimetidirw as an antidote in the treatment of 
acetaminophen poisoning. 
A stud/ was conducted by Abernethy et a l 9 in which acetaminophen was administered 
intravenously to 11 healthy, male subjects on two different occasions. On the first occasion, 
acetaminophen was given alone. On the second occasion, cimetidine 3 0 0 mg was administered 
orally both 6 and 12 hours before the acetaminophen as well as every six hours after, for a 
total of 24 hours. Venous blood samples were collected on both occasions at 5 , 1 5 , 30 and 45 
minutes, as well as 1 , 1 . 5 , 2 , 2 . 5 , 3 , 4 , 6 , 8 and 1 2 hours after the dose of acetaminophen. 
The results show that cimetidine administration had no effect on the overall clearance of 
acetaminophen. Unfortunately, the effect of cimetidine specifically on the oxidative pathway of 
acetaminophen metabolism was not determined because metabolites were rat isolated or 
5 
quantified in the urine. Because the oxidative pathway is quantitatively minor, even if 
cimetidine did inhibit this metabolic pathway, this would not be apparent in the overall 
clearance of acetaminophen. Therefore, in this particular study, it is difficult to draw any 
conclusions as to the effect of cimetidine administration on the oxidative metabolism of 
acetam inophen and its potential usefulness in the treatment of acetaminophen poisoning. 
One final study which examined the effect of cimetidine administration on the oxidative 
metabolism of acetaminophen in humans was conducted by Mitchell et a l . 1 0 In that study, nine 
healthy, mate subjects received acetaminophen orally on two different occasions. On the first 
occasion, or during the control phase, acetaminophen was administered stone. On the second 
occasion, cimetidine 300 mg was administered orally every six hours for a total of 4 8 hours 
before acetaminophen as well as for 2 4 hours after. Blood samples were collected for eight 
hours and urine was collected for 2 4 hours after acetaminophen ingestion from each subject 
on both occasions. The fractional clear vice of acetaminophen by each metabolic pathway was 
then determined. The results reveal that cimetidine administration resulted in a decrease in 
the clearance of acetaminophen by all metabolic pathways when compared to the control phase 
but the sulfation and glucuronldation pathways were decreased to a lesser extent than that of 
the glutathione derived metabolite. However, an examination of the urinary excretion profile 
of unchanged acetaminophen aid metabolites both before and after cimetidine treatment 
revealed that there was no difference in the quantity of the oxidized metabolites recovered in 
the urine. These data suggests that cimetidine would be of little benefit in the treatment of 
acetaminophen overdose. Based on the results of both clinical studies and animal studies which 
do not unequivocally demonstrate the ability of cimetidine to reduce acetaminophen-induced 
hepatic necrosis, the efficacy of cimetidine in the treatment of acetaminophen poisoning 
remains to be determined. 
6 
Metyrapone, a diagnostic drug for hypothalamic-pituitary function, is also a potent 
inhibitor of cytochrome P - 4 5 0 - m e d i a t e d oxidation 3 4 - 3 6 M e t y r a p o n e 1 s a direct acting, 
reversible inhibitor of cytochrome P - 4 5 0 oxidation.35* Metyrapone inhibits microsomal 
function by reverslbly binding with the sixth llgand position of cytochrome P - 4 5 0 thereby 
making this site unavailable for drug o x i d a t i o n . 3 4 Metyrapone has been demonstrated to be a 
stronger ligandfcr phenobarbital-iriducible forms of cytochrome P - 4 5 0 than for those forms 
induced by other substances.3® 
Two animal studies have been published which have demonstrated the protective effect of 
metyrapone administration in experimentally-induced acetaminophen p o i s o n i n g . 1 2 * 1 3 Both 
studies were conducted in mice. To date, no studies have been conducted in man to support the 
potential usefulness of metyrapone administration in the prevention of acetamirraphen-induced 
hepatic necrosis as a consequence of acetaminophen poisoning. 
Both Fossa et a l 1 2 aid Nelson et a l 1 3 have demonstrated that metyrapone administered 
concomitantly with acetaminophen was able to increase the L D 5 q (median lethal dose in 5 0 1 
of the animals tested) in the strains of mice which were studied In the study conducted by 
Fossa et a l , 1 2 mice were given doses of acetaminophen 1ntraper1toneally ranging from 
450 mg/kg to 7 5 0 mg/kg. Half of the mice studied at each dosage level were given metyrapone 
7 5 mg/kg both at one and five hours after acetaminophen. The other half received 
intraperitoneal injections of distilled water. Although the actual L D 5 0 values were not 
reported, Fossa et a l 1 2 did report that the L D 5 0 was increased by 3 0 X with metyrapone 
administration. In the study conducted by Nelson et a l , 1 3 mice were given doses of 
acetaminophen intraperitoneally between 3 0 0 mg/kg and 600 mg/kg. Half of the mice at each 
dosage level were also given metyrapone 4 0 0 mg/kg intraperitoneally concomitantly with the 
7 
acetaminophen. The L D g Q for acetaminophen in this strain of mice was 3 4 0 mg/kg; after 
treatment with metyrapone, the L D 5 0 was increased to 540 mg/kg, an increase of 3 7 1 . 
Additional work also done by Nelson et a l 1 3 demonstrated that the minimum effective dose 
of metyrapone in preventing acetaminophen-induced lethality was 200 mg/kg. The interval of 
time in which a single (tee of metyrapone 4 0 0 mg/kg was effective in preventing death from 
acetaminophen 4 0 0 mg/kg was two hours. After four hours, there was no difference between 
metyrapone treatment and control animals who received only acetaminophen. This suggests 
that glutathione was depleted within four hours after acetaminophen administration and that 
irreversible, hepatocellular necrosis had occurred. In order for metyrapone to prevent 
hepatocellular necrosis in mice, it must be administered within four hours after exposure to 
acetaminophen. 
Nelson et al 1 3 also demonstrated that increasing the do® of metyrapone beyond 
4 0 0 mg/kg was not practical in the treatment for acetaminophen poisoning. Metyrapone at 
doses of 6 0 0 , 8 0 0 and 1 , 0 0 0 mg/kg were associated with significant toxicity. Survival rates 
at each dosage level 96 hours after metyrapone administration were approximately 8 0 , 45 
and 558 respectively. The L D S 0 of metyrapone in the strain of mice studied was 7 6 0 mg/kg. 
Studies of acetaminophen-induced hepatic glutathione depletion have revealed that 
glutathione concentrations are rapidly depressed within two h o u r s , 1 3 but whan animals are 
treated with acetaminophen arid metyrapone simultaneously, the degree of glutathione 
depletion is r e d u c e d . 1 2 » 1 3 It is of Interest that metyrapone 4 0 0 mg/kg administered alone 
resulted in a 2 0 X decrease in liver glutathione concentration when compared to saline 
c o n t r o l . 1 3 Therefore, inspite of metyrapone administration and presumed inhibition of 
cytochrome P - 4 5 0 oxidation, hepatic glutathione concentration is still decreased by 
8 
acetaminophen, although hepatocellular necrosis is presumably reduced. Measurement of 
hepatic glutathione concentration after acetaminophen administration may not be the test 
marker for the development of hepatic necrosis. Perhaps a better measure would be to 
quantitate binding of acetaminophen to hepatocellular macromolecules. 
Histologic study of the livers obtained from mice sacrificed after receiving excessive 
amounts of acetaminophen revealed the presence of centrilobular n e c r o s i s . 1 2 , 1 3 Metyrapone 
administered either simultaneously or within one hour after acetaminophen resulted in 8 
significant reduction in the number of necrotic hepatic cells present on histologic 
examination.1 2» 1 3 It would appear then that metyrapone administration decreases hepatic 
centrilobular necrosis following acetaminophen administration by decreasing or preventing 
the formation of the reactive intermediate and subsequently reduces the rate and extent of 
hepatic glutathione depletion. Based on these findings and the lack of data supporting the use of 
cimetidine in the treatment of acetaminophen poisoning, the present study was undertaken 
utilizing metyrapone. 
METHODS 
The protocol and the consent form for this study were approved by the Institutional 
Review Board (Review Committee for Research with Human Subjects) of the University of 
Utah. Each subject gave written informed consent prior to enrollment in the stucty 
(Appendix A). 
Subjects 
Eight healthy, non-smoking, male volunteers were recruited to participate in the study. 
Renal, liver and hematopoetic funtion were assessed by complete blood count aid S M A - 2 0 . 
9 
Only those volunteers with both a normal physical examination and laboratory parameters 
were allowed to participate. A medication history was also obtained prior to enrollment, and 
no medications other than those required for the study were allowed for one week before or 
during the study itself. It was also requested that all volunteers refrain from the consumption 
of alcoholic beverages during the study. 
Procedures 
The study consisted of two phases. During phase I , each subject received a single oral dose 
of acetaminophen 1 g (two 5 0 0 mg Tylenol® tablets, McNeil Laboratories Inc., Fort 
Washington, P A ) with 150 ml of water after an overnight fast Subjects were allowed a light, 
standardized breakfast approximately one hour before acetaminophen administration. Saliva 
samples were then collected over a two minute interval of time immediately prior to and at 
0 . 5 , 1 , 1 . 5 , 2 , 2 . 5 , 3 , 4 , 6 and 8 hours after acetaminophen administration. Saliva samples 
( 3 ml) were frozen immediately after collection are! were stored at - 2 0 ° C until assayed. 
Blood samples were obtained by venipuncture at 2 , 4 ami 6 hours after acetaminophen 
administration. Blood samples ( 1 0 ml) were drawn via Vacutainer® (Vacutainer Systems, 
Rutherford, N J ) into tubes containing heparin. Plasma was then harvested by centrifugation 
and was frozen at - 2 0 ° C until assayed. Urine samples were collected at 0 - 1 , 1 - 3 , 3 - 5 and 
5 - 7 hours after acetaminophen administration, then as reeded for a total of 2 4 hours. The 
i 
urinary recovery of unchanged acetaminophen and its metabolites has been reported to be up to 
9 5 1 of an administered dose at 2 4 hours after i n g e s t i o n . 7 ' 1 5 Urine samples were collected 
in individual sample bags ( W h i r l Pak Bags®, VWR Scientific, San Francisco, CA) and were 
immediately frozen after collection. All urine samples were stored at - 2 0 ° 0 until assayed. 
Acetaminophen and its conjugates In urine have been reported to be stable at - 2 0 ° C for at least 
1 0 
nine m o n t h s . 3 7 
During phase II, each subject received an oral dose of acetaminophen 1 g and metyrapone 
with 150 ml of water after an overnight fast. Subjects were allowed a light, standardized 
breakfast approximately one h a i r before metyrapone administration. Metyrapone 0 . 7 5 g 
(three 2 5 0 mg Metopirone® tablets, Ciba-Geigy Pharmaceutical Co., Summit, N J ) w a s 
administered a w hour before and three hours after acetaminophen (total dose of metyrapone 
1.5 g). Saliva, blood and urine specimens were collected in the same manner as described in 
phase I (Appendix B). All samples were stored at - 2 0 ° C until assayed. 
All subjects were admitted to the University Hospital, Clinical Research Center on two 
separate occasions and randomly received acetaminophen or acetaminophen with metyrapone. 
Subjects were discharged following the completion of saliva collection, approximately eight to 
to hours after admission. 
The concentrations of acetaminophen in saliva and the concentrations of acetaminophen 
and its sulfate, glucuronide and mercapturic acid conjugates in urine as well as unchanged 
acetaminophen in plasma were determined by high performance liquid chromatography. The 
assay has a lower limit of detection of 0.5 mcg/ml and has a coefficient of variation of less 
than 5 1 at the lowest detectable concentration.38 All concentrations utilized for 
pharmacokinetic calculations were within the sensitivity range of the assay. 
Pharmacokinetic Analysis 
The actual composition of the urinary accretion profile of acetaminophen 8nd its 
metabolites was determined as a percentage of the dose administered. The first order 
elimination rate constant ( K ) was determined by linear least squares regression analysis of 
the log salivary acetaminophen concentration versus time date points. The acetaminophen 
1 1 
half-life ( t l / 2 ) was calculated by the equation t l / 2 = 0.693/K. The acetaminophen t l / 2 
was also estimated from a semi-logarithmic plot of urinary accretion rate (dDu/dt) of 
unchanged acetaminophen versus the midpoint of the urine collection interval ( t m ^ ) . One 
final estimate for t l / 2 was obtained from acetaminophen plasma concentration data from four 
to six hours after acetaminophen administration. Total clearance ( C 1 A p ) was determined by 
both the quotient of administered dose and recovered dose divided by the area under the saliva 
concentration versus time curve extrapolated to infinity. Area under the saliva concentration 
versus time curve (AUC) was calculated by using the linear trapezoidal method and the area to 
infinity ( A U C ^ ) was calculated by adding to AUC the area obtained by dividing the last saliva 
concentration by K. 
The validity of using acetaminophen saliva concentrations as a reliable estimation for 
acetaminophen plasma concentrations is supported in the l i t e r a t u r e . 3 9 " 4 4 The existence of a 
correlation between concentrations of acetaminophen in plasma and saliva has been established 
by Glynn et a l 4 ' and Lowenthal et a l « Saliva to plasma ratios in normal volunteers are 
typically on the order of 1 . 4 over a concentration range of 1 to 20 m c g / m l . 4 3 lowenthal et 
e l 4 2 reported the saliva to plasma ratios 1n a croup of eight subjects composed of both 
anephric patients and healthy volunteers to range from 0.91 to 1.30 with an average ratio of 
1.08. 
Statistical Analysis 
Comparison of the pharmacokinetic parameters K , t l / 2 , AUC«> and Cl^p; the fractional 
excretion of unchanged acetaminophen and metabolites as a percentage of the administered 
1 2 
dose, before ami after metyrapone administration, was performed by using a non-parametric 
statistical test, the Wilcoxon-Mann-Whitney t e s t 4 5 * 
Differences in parameters obtained from the two phases of the study were considered to be 
attributable to metyrapone treatment aft a level of p less than 0 . 0 5 , two tailed analysis. All 
results are reported as the mean t  standard deviation. 
RESULTS 
Urinary Excretion Profile 
The actual composition of the urinary excretion profiles of acetaminophen before and after 
metyrapone administration are shown in Tables 1 and 2. Subject * 7 was excluded from data 
analysis before metyrapone treatment (Table 1) because of unreliable total urinary recovery 
of acetaminophen and metabolites. Subject * 4 was excluded from data analysis after 
metyrapone administration (Table 2 ) for the same reason. 
Metyrapone administration resulted in a statistically significant reduction in the 
fractional excretion of acetaminophen as the glucuronide conjugate ( p < 0.006). The 
fractional excretion of glucuronide decreased from 52.3 ± 9 , 9 1 to 36.0 ± 8 . 5 1 . The 
fractional excretion of the sulfate derived conjugate increased from 1 7 . 2 ± 4 . 0 1 to 
2 6 . 3 * 6 . 6 * ( p < 0.006). The fractional excretion of the mercapturic acid metabolite 
increased from 1.5 ± 0 . 6 1 to 3 . 4 ± 1 . 4 1 after metyrapone treatment. This increase was 
found to be statistically significant ( p < 0 . 0 2 6 ) , Metyrapone administration had no effect on 
the fractional excretion of unchanged acetaminophen, The fractional excretion of unchanged 
acetaminophen before metyrapone was 3.6 ± 0 . 7 1 and after was 3.4 * 1 . 0 1 . The total 
urinary recovery of acetaminophen, expressed as a percentage of the dose administered, 
was 7 4 . 5 ± 1 . 2 1 before metyrapone aid 69.1 ± 1 3 . 0 1 after. This difference was not found 
1 3 
to te statistically significant. 
Pharmacokinetic Parameters 
The first-order elimination rate constant, t l / 2 and A U C ^ determined from 
semi-logarithmic plot of saliva concentration versus time, before and after metyrapone 
administration, w e shown in Tables 3 and 4. The semi-logarithmic plots of saliva 
concentration versus time used for the determination of K and t l / 2 appear in Figures 2 
through 9. Subject * 1 was excluded from data analysis because of marked discontinuity in 
saliva concentration versus time data thereby making it impossible to estimate a reliable K, 
Subjects * 7 and * 4 were excluded from determinations of A U C ^ before (Table 3 ) and after 
metyrapone administration (Table 4 ) respectively for reasons detailed previously. Table 5 
shows the ratios of saliva to plasma acetaminophen concentrations determined four and six 
hours after acetaminophen administration before and after metyrapone. Ratios were not 
determined two hours after acetaminophen administration to ensure that acetaminophen 
absorption was complete. The ratios of saliva to plasma acetaminophen concentration before 
metyrapone administration at four and six hours were 1 . 1 8 ± 0 . 4 8 and 1.08 ± 0 . 1 2 
respectively. The ratios were 1 . 2 4 ± 0 . 5 8 aid 0.9S ± 0 . 3 7 after metyrapone treatment. 
The first-order elimination rate constant decreased as a result of metyrapone 
administration. The K decreased from a rate of 0 . 2 9 ± 0.04 h r " 1 W o r e metyrapone to 
0.22 ± 0.06 h r " 1 after metyrapone. This decrease was statistically significant (p < 0 . 0 1 8 ) . 
Because of the decrease in K , there was a resultant increase in t l / 2 . The 11 /2 increased from 
2.43 ± 0 . 2 8 hr to 3.46 * 1 . 1 5 hr. This increase in t l / 2 was also statistically significant 
( p < 0 , 0 1 8 ) . Comparisons of ansa under the curve extrapolated to infinity data revealed that 
1 4 
metyrapone treatment resulted in a statistically significant increase in A U C ^ ( p < 0 . 0 1 6 ) . 
Metyrapone administration resulted in an increase of AUC«> from 5 3 . 0 7 ± 4.65 mg-hr/1 to 
7 2 . 5 1 ± 1 8 . 1 6 mg-hr/1. 
The first-order elimination rate constant was also estimated from semi-logarithmic plot 
of urinary excretion rate of unchanged acetaminophen versus time before and after 
metyrapone administration (Figures 10 through 1 7 ) . The estimations for K obtained from 
these plots are listed in Table 6. Subject * 1 was not included in the analysis after 
metyrapone treatment because of marked discontinuity In the urinary excretion rate versus 
time plot. The urinary excretion rate constant decreased as a result of metyrapone treatment. 
The K decreased from 0 . 2 8 ± 0 . 1 3 h r - 1 to 0 . 1 8 i 0.05 hr""1 after metyrapone. This 
decrease however did not reach statistical significance. As a result of the decrease in K after 
metyrapone treatment, the half-l i fe Increased from 3.04 ± 1 .48 hr to 4 . 2 8 ± 1 . 6 7 hr. These 
data are also shown in Table 6. The increase in 1 1 / 2 also did not reach statistical significance. 
One final estimate for half-life was obtained from semi-logarithmic plots of plasma 
concentration versus time from four to six hours after acetaminophen administration. These 
data are shown composltly with the other estimates for t l / 2 In Table 7 . Plasma t l / 2 
estimations showed changes after metyrapone treatment similar to those reported f i r t l / 2 
estimations from semi-logarithmic plots of saliva concentration versus time and urinary 
excretion rate determinations. The t l / 2 estimated from plasma data increased from 
2.62 ± 1 . 2 1 hr to 4.63 ± 1 . 7 1 hr as a result of metyrapone administration. This increase 
was found to be statistically significant ( p < 0 . 0 2 2 ) . 
The apparent and actual clearances of acetaminophen both before and after metyrapone 
treatment are shown in Table 8. Subject * 1 was excluded from data analysis both before and 
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after metyrapone administration because K could not be determined from saliva versus time 
date therefore making it Impossible to determine A U C ^ . Subject * 7 was excluded from data 
analysis before metyrapone treatment and subject * 4 was excluded after metyrapone 
treatment because AUCqo could not be determined. 
The apparent clearance of acetaminophen decreased from 4.64 ± 0.54 ml/min/kg to 
3 . 4 3 ± 0 . 8 3 ml/min/kg after metyrapone ( p < 0 . 0 1 6 ) . The actual clearance of 
acetaminophen also showed a statistically significant decrease after metyrapone 
administration ( p < 0 . 0 2 6 ) . The actual clearance of acetaminophen decreased from 
3 . 4 2 ± 0 . 7 6 ml/min/kg before metyrapone treatment to 2.31 t 0.64 ml/min/kg after 
metyrapone. 
DISCUSSION 
The overall urinary excretion profile and recovery of acetaminophen before metyrapone 
administration differs somewhat from that which has been previously reported in the 
literature 7 . 8 , 1 0 , 1 5 , 4 6 - 4 9 l n t h e p r e s c n l s t u ( V > the urinary recovery of the 
glucuronide and sulfate derived conjugates were 52.3 ± 9 . 9 1 and 1 7 . 2 ± 4 . O X respectively, 
while 1.5 ± 0.658 and 3 . 6 ± 0.758 were recovered as the mereapturic acid metabolite and 
unchanged acetaminophen. In young, healthy, male subjects approximately 6 0 , 30 and 558 of 
a 1 g dose of acetaminophen appears in the urine as the glucuronide, sulfate and mercapturic 
acid derivatives respectively, while approximately 458 will be eliminated as unchanged 
acetaminophen within a 2 4 hour p e r i o d . 1 5 » ' 6 One possible explanation for this discrepency 
could be a difference in the extent of absorption of acetaminophen. In a i r study, subjects were 
allowed a light, standardized breakfast approximately one hour prior to acetaminophen 
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aAninistration during both phases of the study. The meal was provided in order to prevent 
gastrointestinal complaints as the result of metyrapone treatment. The administration of food 
could have decreased both the r a t i end the extent of acetaminophen absorption on both 
occasions. However, there was no difference in the extent of acetaminophen absorption 
between the two phases of the study as determined by the total urinary recovery of unchanged 
acetaminophen and metabolites. 
In this investigation, metyrapone administration resulted in a significiant reduction in 
glucuronidation, a non-toxic metabolic pathway of acetaminophen (Figure 1 , metabolic 
pathway A). Because of this reduction in glucuronidation, and the presence of parallel, 
competing, metabolic pathways for acetaminophen metabolism, the fraction of the 
administered dose recovered as the sulfate conjugate increased (Figure I , metabolic pathway 
B). The explanation for this shift in metabolic pathways from glucuronidation to sulfation is 
that metyrapone competes with acetaminophen for glucuronidation. Metyrapone is converted 
to a reduced metabolite by the P - 4 5 0 mixed-function oxidase s y s t e m . 5 0 - 5 2 Metyrapone and 
its reduced metabolite are then conjugated with glucuronic acid and excreted in the urine. 
A comparison of the actual urinary excretion profiles of acetaminophen before and after 
metyrapone administration demonstrates that metyrapone may not be of benefit in the 
prevention of acetaminophen-induced hepatic necrosis if the protective effect is presumed to 
be the direct result of the inhibition of cytochrome P-450-mediated oxidation. A comparison 
of the actual fraction of the administered dose of acetaminophen recovered as the mercapturic 
acid metabolite before and after metyrapone administration revealed an increase in the 
urinary recovery of that metabolite after metyrapone treatment. Moreover, although 
metyrapone ma/ have inhibited P - 4 5 0 - m e d i a t e d oxidation of acetaminophen to the reactive 
intermediate, our results suggest that glucuronidation was Inhibited to a greater extent. For 
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the optimal management of acetaminophen overdose, all agents being considered should rot only 
inhibit the formation of the Tractive intermediate but also should rot impair the clearance of 
acetaminophen via its ram-toxic metabolic pathways. It is the sum of these metabolic 
pathways when parallel, competing metabolic pathways are present which determines the 
overall elimination of the drug (Figure 18). Therefore, one cannot only examine the effect of 
a potential antidote on the oxidative metabolic pathway in the treatment of acetaminophen 
poisoning. 
The mean ratios of saliva to plasma acetaminophen concentration determined here are 
similar to those reported by other i n v e s t i g a t o r s . 4 2 ' 4 4 Adithan and Thangam4 4 reported a 
mean saliva to plasma ratio of 1 . 1 4 ± 0 . 0 5 from fifteen minutes to four hours after 
acetaminophen administration. Danhoff and B r e i m e r 4 3 report a mean ratio of saliva to 
plasma of 1 . 4 0 which was obtained from a review of the literature. In the present study, 
ratios of 1 . 1 8 ± 0 . 4 8 and 1 .08 ± 0 . 1 2 were obtained four ami six tars respectively after 
acetaminophen administration. 
The t1 / 2 of acetaminophen determined from saliva concentration versus time data before 
metyrapone administration was 2 . 4 3 t 0 . 2 8 hr. Mean terminal elimination phase t l / 2 
values in the range of 1 . 9 5 to 2.60 hr have been reported previously with normal, 
therapeutic doses of acetaminophen, 7 " 1 0 - 1 6 > 5 3 The t l / 2 of acetaminophen is 
prolonged in patients who are severely intoxicated as the result of capacity limited 
pharmacokinetics.54 The t l / 2 may also be prolonged In patients who suffer subsequent 
hepatic i n j u r y . 2 Prolonged t l / 2 has been suggested to be a valuable predictor for the 
development of hepatic necrosis in acetaminophen poisoning.2- 2 1 When acetaminophen was 
administered concurrently with metyrapone the elimination t l / 2 was observed to be 
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increased to 3 . 4 6 ± 1 . 1 5 hr. This finding might also be explained by the impaired elimination 
of acetaminophen by metyrapone via one of its primary, non-toxic metabolic pathways 
through competition for glucuronidation. As a result of this competition, the terminal 
elimination t l / 2 of acetaminophen is prolonged. 
Abernethy et a l 5 4 reported a similar finding when acetaminophen was administered 
concurrently with probenecid. Acetaminophen t l / 2 was prolonged by probenecid treatment 
from 2 . 5 1 ± 0 . 1 6 hr to 4 . 3 0 ± 0 . 2 3 hr. The urinary excretion of acetaminophen as the 
glucuronide metabolite was decreased from 4038 to 1 3 1 and the fraction excreted as the 
sulfate metabolite Increased from 3 3 1 to 5 0 1 . Although the exact mechanism by which 
probenecid impairs the clearance of acetaminophen is unknown, proposed mechanisms include: 
inhibition of glucuronyl transferase activity; impaired renal excretion of the glucuronide 
metabolite with subsequent deconjugatlon in plasma back to the parent compound; competition 
of probenecid with acetaminophen for available glucuronic a c i d . 5 5 
Estimations for acetaminophen 1 1 / 2 were also available from urinary accretion rate plot 
data and plasma concentration versus time data before and after metyrapone administration. 
These estimations for t1 /2 also revealed an increase In acetaminophen t l / 2 as the result of 
metyrapone administration. Therefore, all estimations for acetaminophen t l / 2 , regardless of 
the method of determination, consistently demonstrated an increase in elimination t l / 2 after 
metyrapone treatment. 
Comparisons of A l I C ^ before and after metyrapone administration revealed a statistically 
significant increase in this pharmacokinetic parameter. The A U G * , before metyrapone 
administration was found to to 5 3 . 0 7 * 4 . 6 5 mg-hr/1. This is similar to the work done by 
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Perucca et a l ^ 3 who reported an A U C ^ of -49.4 ± 1 .8 mg-hr/1 with 6018 urinary recovery of 
unchanged acetaminophen and metabolites after administering acetaminophen 1 g orally to six, 
healthy volunteers. The increase in AUC«» seen after metyrapone administration can be 
explained by the decrease in K which was the direct result of metyrapone administration. The 
first-order elimination rate constant was decreased because of decreased elimination of 
acetaminophen via glucuronidation, the primary metabolic pathway of acetaminophen 
metabolism. 
The apparent clearance of acetaminophen (determined by the dosage of acetaminophen 
administered) decreased after the administration of metyrapone as a result of the decrease in 
K. The apparent clearance of acetaminophen in our study before metyrapone 
administration was 4.64 t 0 . 5 4 ml/min/kg. Muck low et al4® reported a clearance of 
3.90 ± 1 . 0 7 ml/min/kg after administering 1 , 5 g of acetaminophen orally to a heterogeneous 
group of London factory and office workers. The apparent clearance of acetaminophen 
( C 1 A P / F ) is reported here because the systemic availability of the acetaminophen product 
used in this investigation was unknown. Previous investigations®3»^ have reported that the 
fraction of the administered dose of acetaminophen reaching the systemic circulation Is dose 
dependent and decreases from approximately 9 0 1 after oral administration of 1 to 2 g to 6035 
after 0.5 g. A variable amount of drug is lost to first pass metabolism with saturation of first 
pass metabolism occurring with doses greater than 0.5 g. Ameer et al®7 recently reported the 
systemic availability of Tylenol® braid acetaminophen tablets to be 7 9 1 after oral 
administration of 650 mg in the form of two 325 mg tablets. 
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CONCLUSION 
These findings with normal, therapeutic doses of acetaminophen in healthy volunteers do 
not support the use of metyrapone as an antidote for acetaminophen poisoning. In this 
investigation, metyrapone administration failed to decrease the formation of the reactive 
intermediate as determined by quantitation of the urinary recovery of the mercapturic acid 
metabolite. In addition, these data suggest that metyrapone could potentially worsen the 
severity of acetaminophen intoxication by decreasing elimination via glucuronidation, a 
non-toxic metabolic pathway and increasing the fraction of drug available to undergo 
P-450-mediated oxidation to the reactive intermediate. Therefore, any P - 4 5 0 
mixed-function oxidase inhibitors which may be considered as potential antidotes for the 
treatment of acetaminophen poisoning in the future must to comprehensively evaluated in 
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Figure I . Parallel, competing, metabolic pathways of a c e t a m i n o p h e n . 
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F i g u r e 2 . S e m i - l o g a r i t h m i c p l o t o f s a l i v a c o n c e n t r a t i o n of unchanged 
a c e t a m i n o p h e n v e r s u s t i m e d a t a p o i n t s f o r s u b j e c t - * 1 b e f o r e ( • ) and a f t e r ( o ) 
m e t y r a p o n e a d m i n i s t r a t i o n . T h e s e data w e r e o b t a i n e d f o l l o w i n g s i n g l e o r a l doses 
o f a c e t a m i n o p h e n 1 . 0 g. 
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F i g u r e 3. S e m i - l o g a r i t h m i c plot of saliva concentration of unchanged 
acetaminophen v e r s u s t i m e data points f o r subject * 1 before ( • ) and after ( o ) 
metyrapone administration. These data w e r e obtained following single oral closes 
of acetaminophen 1 . 0 g. 
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F i g u r e 4. S e m i - l o g a r i t h m i c plot of saliva concentration of unchanged 
acetaminophen versus t i m e data points f o r subject * 3 before ( • ) and after ( O ) 
metyrapone administration. These data w e r e obtained following single oral doses 
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F i g u r e 5, S e m i - l o g a r i t h m i c plot of saliva concentration of unchanged 
acetaminophen v e r s u s t i m e data points f o r subject * 4 before ( • ) and after ( o ) 
metyrapone administration. These data w e r e obtained following single oral doses 
o f acetaminophen 1 . 0 g. 
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F i g u r e 6 . S e m i - l o g a r i t h m i c p l o t o f s a l i v a c o n c e n t r a t i o n o f unchanged 
a c e t a m i n o p h e n v e r s u s t i m e d a t a p o i n t s f o r s u b j e c t - * 5 b e f o r e ( • ) and a f t e r ( o ) 
m e t y r a p o n e a d m i n i s t r a t i o n . T h e s e d a t a w e r e o b t a i n e d f o l l o w i n g s i n g l e o r a l doses 
o f a c e t a m i n o p h e n 1 . 0 g. 
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F i g u r e 7 . S e m i - l o g a r i t h m i c plot of saliva concentration of unchanged 
acetaminophen v e r s u s t i m e data points f o r subject ~ * 6 before ( • ) and after ( 0 ) 
metyrapone administration. These data w e r e obtained following single oral doses 
o f acetaminophen 1 . 0 g. 
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F i g u r e 8. S e m i - l o g a r i t h m i c plot of saliva concentration of unchanged 
acetaminophen v e r s u s t i m e data points f o r subject * 7 before ( • ) and after ( o ) 
metyrapone administration. These data w e r e obtained following single oral doses 
o f acetaminophen 1 . 0 g. 
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F i g u r e 9 . S e m i - l o g a r i t h m i c plot of saliva concentration of unchanged 
acetaminophen v e r s u s time (fata points f o r subject * 8 before ( • ) and after ( o ) 
metyrapone adm inistration. These data w e r e obtained following single oral doses 
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MIDPOINT OF COLLECTION I N T E R V A L 
(HR) 
F i g u r e 1 0 . S e m i - l o g a r i t h m i c plot of u r i n a r y excretion rate of unchanged 
acetaminophen v e r s u s midpoint o f collection interval for subject • * 1 before ( • ) 
and after ( o ) metyrapone a d m i n i s t r a t i o n . These data w e r e obtained following 
single o r a l doses of acetaminophen 1 . 0 g. 
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a c e t a m i n o p h e n v e r s u s m i d p o i n t o f c o l l e c t i o n i n t e r v a l f o r s u b j e c t * 2 b e f o r e ( • ) 
and a f t e r ( o ) m e t y r a p o n e a d m i n i s t r a t i o n . T h e s e d a t a w e r e o b t a i n e d f o l l o w i n g 
s i n g l e o r a l doses o f a c e t a m i n o p h e n 1 . 0 g. 
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Figure 1 2 . S e m i - l o g a r i t h m i c plot of u r i n a r y excretion rate of unchanged 
acetaminophen v e r s u s midpoint of collection i n t e r v a l f o r subject * 3 before ( • ) 
and after ( o ) metyrapone administration. These data w e r e obtained following 
single o r a l doses of acetaminophen 1 . 0 tj. 
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F i g u r e 1 3 . S e m i - l o g a r i t h m i c plot of u r i n a r y excretion rate of unchanged 
acetaminophen v e r s u s midpoint of collection i n t e r v a l f o r subject * 4 before ( • ) 
and after ( o ) metyrapone administration. These data w e r e obtained following 
single oral doses of acetaminophen 1 . 0 g. 
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F i g u r e 1 4 . S e m i - l o g a r i t h m i c plot o f u r i n a r y e x c r e t i o n rate of unchanged 
acetaminophen v e r s u s midpoint of collection i n t e r v a l f o r subject * 5 before ( • ) 
and after ( o ) metyrapone administration. These data w e r e obtained following 
single o r a l doses of acetaminophen 1 . 0 g. 
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F i g u r e 1 6 . S e m i - l o g a r i t h m i c plot of u r i n a r y excretion rate of unchanged 
acetaminophen v e r s u s midpoint of collection i n t e r v a l f o r subject * 7 before ( • ) 
and after ( o ) metyrapone administration. These data w e r e obtained following 
single o r a l doses of acetaminophen 1 . 0 g. 
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F i g u r e 1 7 . S e m i - l o g a r i t h m i c plot of u r i n a r y excretion rate of unchanged 
acetaminophen v e r s u s midpoint of collection i n t e r v a l f o r subject - * 8 before ( • ) 
and after ( o ) metyrapone administration. These data w e r e obtained f o l l o w i n g 
single oral doses of acetaminophen 1 . 0 g. 
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Figure 18. Influence of parallel, competing, metabolic pathways in determining the 
elimination of acetaminophen. Fraction of drug converted to toxic intermediate is dependent on 
both k j and 1(2-
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Table 1. Actual composition of urinary excretion profile of acetaminophen and its 
metabolites before metyrapone administration 
Mean Fractional Excretion ( % Recovered)* 
Subject Total Dose 
Number Glucuronide Sulfate Mercapturic Acid Unchanged? Recovered 
1 6 4 . 8 13.6 0 . 4 4 . 3 83.0 
2 4 9 . 3 16.9 2 . 0 3.0 7 1 . 2 
3 4 5 . 0 20.0 1 . 2 4 . 7 7 0 . 9 
4 4 1 . 0 16.0 2 . 2 3.8 63.0 
5 6 6 . 9 2 4 . 2 1 .1 3.0 95.2 
6 4 7 . 4 1 2 . 2 2 . 0 3.2 6 4 . 2 
8 5 1 . 4 1 7 . 2 1 . 4 3.3 7 3 . 4 
Mean 5 2 . 3 1 7 . 2 1 .5 3.6 7 4 . 5 
Standard 
Deviation 
9.9 4 . 0 0 . 6 0 . 7 1 1 . 2 
j|F * ^ ^ 1 1 1 - IK I • — — P ' » I I—I . . I « — — • I 
Expressed as percentage of acetaminophen dose administered. 
0 Unchanged acetaminophen. 
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Tabic 2. Actual composition of urinary excretion profile of acetaminophen and its 
metabolites after metyrapone administration 
Mean Fractional Excretion ( % Recovered) 
Subject Total Dose 
Number Glucuronide Sulfate MercapturicAcid Unchanged* Recovered 
1 4 7 . 6 20.9 3 . 9 3 . 8 7 6 . 2 
2 2 1 . 4 2 2 . 0 1 . 8 2.1 4 7 . 2 
3 4 3 . 0 39.8 1 . 3 5.2 8 9 . 3 
5 3 9 . 3 2 9 . 4 3 . 3 2.8 7 4 . 8 
6 3 4 . 5 2 2 . 8 3 . 7 3 . 1 6 4 . 0 
7 3 5 . 2 2 2 . 6 5 . 0 3.1 6 5 . 9 
8 3 1 . 0 26.8 4 . 8 3.9 6 6 . 5 
Mean 3 6 . 0 26.3 3 . 4 6 9 . 1 
Standard 
Deviation 
8.5 6.6 1 . 4 1.0 1 3 . 0 
Expressed as percentage of acetaminophen dose administered. 
0 Unchangad acetaminophen. 
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Table 3. Pharmacokinetic parameters of acetaminophen before metyrapone administration 
determined from semi-logarithmic plot of saliva concentration versus time 
Subject 
Number K ( H r " ' ) * t l / 2 ( H r ) ° A U C 0 0 ( m g - H r / L ) + 
2 0 , 2 7 2 . 5 7 5 4 . 3 7 
3 0 . 2 7 2 . 5 7 5 7 . 7 0 
4 0 . 2 8 2 . 4 8 56.01 
5 0 . 3 2 2 . 1 6 4 4 . 3 5 
6 0.36 1 . 9 2 5 3 . 3 2 
7 0 . 2 6 2.66 NA 
8 0 . 2 6 2 . 6 6 5 2 . 6 6 
Mean 0 . 2 9 2 . 4 3 5 3 . 0 7 
Standard 0 . 0 4 0.28 4 . 6 5 
Deviation 
* First order elimimation rate constant 
0 Half-life. 
+ Area under the saliva concentration versus time curve extrapolated to infinity. 
Table 4. Pharmacokinetic parameters of acetaminophen after metyrapone atoinistration 
determined from semi-logarithmic plot of saliva concentration versus time 
Subject 
Number K U H r " 1 } * t 1 / 2 ( H r ) ° A U C o e ( m g - H r / L ) + 
2 0 . 1 7 4 . 0 8 83.45 
3 0 . 1 2 5 . 7 8 1 0 2 . 7 4 
4 0 . 2 2 3 . 1 5 NA 
5 0.26 2 . 6 6 5 3 . 8 7 
6 0 . 2 9 2 . 3 9 6 4 . 1 7 
7 0 . 2 3 3.01 5 8 , 4 1 
8 0 . 2 2 3 . 1 5 7 2 . 4 3 
Mean 0 . 2 2 3 . 4 6 7 2 . 5 1 
Stamford 
Deviation 
0.06 1 . 1 5 1 8 . 1 6 
* F i r s t order elimimatlon r a t e constant. 
0 H a l f - l i f e . 
4 Area under the saliva concentration versus time curve extrapolated to infinity. 
Table 5. Ratios of saliva to plasma acetaminophen concentrations determined four and six 
hours after acetaminophen administration both before and after metyrapone 
Before Metyrapone After Metyrapone 
Sub|6ci 
Number 4.0 ( H r ) 6.0 ( H r ) 4.0 ( H r ) 6.0 ( H r ) 
2 0 . 9 2 1.04 0.88 0 . 6 2 
3 1 . 0 7 1.21 0.96 1 . 1 4 
4 1 . 6 7 0.96 1 .95 1 . 0 5 
5 0 . 7 0 1 .24 1 . 1 8 0 . 5 8 
6 1 .01 1.08 0.63 0 . 6 8 
7 2 . 0 2 0.92 2 . 1 5 1 . 6 3 
8 0.90 1 . 1 4 0.95 0 . 9 4 
Mean 1 . 1 8 1.08 1 . 2 4 0 . 9 5 
Standard 
Deviation 
0 . 4 8 0 . 1 2 0 . 5 8 0 . 3 7 
4 6 
Table 6. F i r s t - o r d e r elimination rate constant and half-life of acetaminophen determined 
from semi-logarithmic plot of excretion rate versus midpoint of collection interval before 
and after metyrapone administration 
Before Metyrapone After Metyrapone 
Subject 
Number K f H r " 1 ) * t l / 2 ( H r ) ° K ( H r " 1 ) * t ! / 2 ( H r ) ° 
1 0 . 2 5 2 . 7 7 NA NA 
2 0 . 4 6 1.51 0 . 1 6 4 . 3 3 
3 0 . 2 8 2 . 4 8 0 . 1 9 3 . 6 5 
4 0 . 4 7 1 . 4 7 0 . 2 1 3 . 3 0 
5 0 . 2 7 2 . 7 7 0.09 7 . 7 0 
6 0 . 1 5 4 . 6 2 0 . 1 4 4 . 9 5 
7 0 . 2 4 2.89 0 . 2 1 3 . 3 0 
8 0 . 1 2 5 . 7 8 0.25 2 . 7 7 
Mean 0 . 2 8 3 . 0 4 0 . 1 8 4 . 2 8 
Standard 
Deviation 
0 . 1 3 1 . 4 8 0.05 
* 
1 . 6 7 
* First order  elimination rate constant 
0 Half-life. 
Table 7 . Comparison of half-lives obtained from saliva concentration versus time, 
excretion rate plot and plasma concentration versus time before and after metyrapone 
administration 
Before Metyrapone After Metyrapone 
Subject 
Number 
t l / 2 
( H r 5 * 
t l / 2 
( H r ) ° 
t l / 2 
( H r ) + 
t l / 2 
( H r ) * 
t l / 2 
( H r ) ° 
1 1 / 2 
( H r ) + 
1 NA 2 . 7 7 2 . 4 8 NA NA NA 
2 2 . 5 7 1.51 2 . 3 1 4 . 0 8 4 . 3 3 4 . 9 5 
3 2 . 5 7 2 .48 2 . 1 0 5 . 7 8 3.65 3.85 
4 2 . 4 8 1 . 4 7 NA 3 . 1 5 3.30 4 . 9 5 
5 2 . 1 6 2 . 7 7 1 . 9 2 2 . 6 6 7 . 7 0 7 . 7 0 
6 1 . 9 2 4 . 6 2 2 . 1 0 2 . 3 9 4.95 3.01 
7 2 . 6 6 2 . 8 9 5 . 3 3 3 . 0 1 1 1 0 WW NA 
8 2 . 6 6 5 . 7 8 2 . 1 0 3 . 1 5 2 . 7 7 3 . 3 0 
Mean 2 . 4 3 3.04 2 . 6 2 3 . 4 6 4 . 2 8 4 . 6 3 
Standard 
Deviation 
0 . 2 8 1 .48 1 . 2 1 1 . 1 5 1 . 6 7 1 . 7 1 
* Half- life determined from semi-logarithmic plot of saliva concentration versus time, 
0 Half-life determined from semi-logarithmic plot of urinary excretion rate versus 
midpoint of collection interval. 
+ Half-life determined from semi-logarithmic plot of plasma concentration versus time. 
4 8 
Table 8. Total clearance of unchanged acetaminophen before m l after metyrapone 
administration determined from area under the saliva concentration versus time curves 
extrapolated to infinity 
Before Metyrapone After Metyrapone 
Subject C 1 A P / F * C I ^ j 0 
Number (ml/min/kg) (ml/min/kg) 
c i A p / r 
(ml/min/kg) (ml/min/kg) 
2 4 . 3 6 3 . 1 0 2 . 8 4 1 . 3 4 
3 3 . 7 5 2 . 6 6 2 . 1 0 1.88 
4 5 . 2 5 3 . 4 2 NA NA 
5 5 . 1 1 4 . 8 7 4 . 2 1 3 . 1 5 
6 4 . 7 5 3 . 0 8 3 . 9 5 2.53 
7 NA NA 4 . 1 1 2 . 7 1 
8 4 . 6 5 3 . 4 2 3 . 3 8 2 . 2 5 
Mean 4 . 6 4 3 . 4 2 3 . 4 3 2.31 
Standard 
Deviation 
0 . 5 4 0 . 7 6 0 . 8 3 0.64 
Apparent clearance of acetaminophen, 





Informed Consent for Human Subjects Involved in Research 
Project Title: The Effect of Metyrapone on the Elimination Kinetics and Metabolic Fate of 
Acetaminophen in Man 
The purpose of this study is to evaluate the effect of the drug metyrapone on the elimination of 
another drug, acetaminophen. Acetaminophen is a widely used non-prescription analgesic and 
antipyretic sold under brand names such as Tylenol®, Datril®, and Panadol®. The usual 
adult dosage is 6 5 0 milligrams or two tablets; the FDA permits 1.0 gram to be recommended 
for use on the product label. When taken in large amounts (more than 10 grams as a single 
dose) the drug may produce both liver and kidney damage. Unlike aspirin, It does not cause 
stomach irritation. This investigation involves the oral administration of 1 .0 gram of 
acetaminophen on two seperate occasions, in the form of Tylenol® tablets. On one occasion, 
Metopirone® (metyrapone, a total of 1 5 0 0 milligrams or 1.5 grams) will be also given 
orally with the acetaminophen. Metyrapone is used to test pituitary gland function aid in 
animals has been used to treat experimentally-induced acetaminophen overdose. Following 
normal doses of metyrapone ( 7 5 0 milligrams every 4 hours for six doses) some patients 
experience some drowsiness. Other minor side effects occasionally reported with metyrapone 
Include headache end upset stomach. After receiving the acetaminophen on both occasions you 
will be asked to collect your saliva and urine at defined intervals for 24 hours. Three blood 
samples (approximately 2 tablespoons) w i l l be taken from a vein in your arm at 2 , 4 and 6 
hours after taking the acetaminophen also on both occasions. 
The benefits to you from participating in this study include a free physical examination and 
laboratory tests to determine that you are healthy prior to enrollment in the study. You will 
receive $ 3 0 . 0 0 for each of the two pluses of the study that you complete. The study will take 
2 to 3 weeks to complete and there will be a total of 1 0 subjects selected to participate. 
The risks from participating in this study include the possibility of side effects from 
metyrapone such as headache, upset stomach and 3edet1on. Taking blood samples can be painful 
and can sometimes cause bruising. 
You may ask questions at any time regarding this study by contacting either Dr. R. E. Oalinsky 
at 5 S 1 - 7 1 0 3 or D r . D. E. Rollins at 5 8 1 - 5 1 1 7 . All records will be the property of the 
investigators and will be confidential. Any research data released or published will not 
identify the volunteers by name. In the event that you sustain physical injury resulting from 
the research project in which you are participating, the University of Utah will provide you, 
without charge, emergency and temporary medical treatment not otherwise covered by 
insurance. Furthermore, if your injuries are caused by negligent acts or omissions by 
University employees acting in the course end scope of their employment, the University may 
be held liable, subject to limitations prescribed by law, for additional medical costs and other 
damages that you may sustain. If you believe that you have suffered a physical injury as a 
result of participation In this research program, please contact the Office of Research 
Administration at 5 8 1 - 6 9 0 3 . 
Your participation In this investigation is voluntary and you may withdraw from the study at 
any time. Refusal to participate will involve no penalty or loss of benefits to which you are 
otherwise entitled. 
Signature of Volunteer-
Signature of investigator: 
Date: 
APPENDIX i 
The Effect of Metyrapone on the Elimination Kinetics and Metabolic 
Fate of Acetaminophen in Man 
A C E T A M I N O P H E N S A M P L E C O L L E C T I O N P H A S E I 
Patient Name: Date:, 
T I M E P R O C E D U R E S C H E D U L E D T I M E A C T U A L T I M E 
Minus 0 . 5 Saliva 1 
Zero Acetaminophen 
0 . 5 Saliva 2 
1.0 Saliva 3 
Urine 1 
1.5 Saliva 4 
2 . 0 Saliva 5 
Plasma 1 
2 . 5 Saliva 6 
3.0 Saliva 7 
Urine 2 
4 . 0 Saliva 8 
Plasma 2 
5 . 0 Urine 3 
6 . 0 Saliva 9 
Plasma 3 
7 . 0 Urine 4 
8 , 0 Saliva 1 0 
A C E T A M I N O P H E N S A M P L E C O L L E C T I O N P H A S E I (CONTINUED) 
Patient Name: D a t e , — ( , 
P R N U R I N E ACTUAL T I M E 
The Effect of Metyrapone on the Elimination Kinetics and Metabolic 
Fate of Acetaminophen in Man 
A C E T A M I N O P H E N S A M P L E C O L L E C T I O N P H A S E l i 
Patient Name: Data 
T I M E P R O C E D U R E S C H E D U L E D T I M E A C T U A L T I M E 
Minus 1 . 0 Metyrapone 
Minus 0 . 5 Saliva 1 
Zero Acetaminophen 
0 . 5 Saliva 2 
1 . 0 Saliva 3 
Urine 1 
1 .5 Saliva 4 
2 . 0 Saliva 5 
Plasma 1 
2 . 5 Saliva 6 
3 . 0 Saliva 7 
Urine 2 
Metyrapone 
4 . 0 Saliva 8 
Plasma 2 
5 . 0 Urine 3 
6 . 0 Saliva 9 
Plasma 3 
7 . 0 Urine 4 
8 . 0 Saliva 10 
A C E T A M I N O P H E N S A M P L E C O L L E C T I O N P H A S E II (CONTINUED) 
Patient None: Date: ' ' 
P R N U R I N E A C T U A L T I M E 
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